James E. Hattersley
Senior Vice President of Business DevelopmentMr. James E. Hattersley, M.S, B.A. is Member of Supervisory Board at Freya Pharma Solutions B.V. from January 1, 2025. He serves as Director at Temple Therapeutics. B.V. He served as the Vice President of Corporate Business Development at Antares Pharma Inc. since February 2005. Mr. Hattersley served as Senior Director of Business Development at Eurand, Inc., a global drug delivery and specialty pharma company. While there, he was responsible for identifying partners and executing a series of development and commercial license agreements. Before Eurand, Mr. Hattersley was employed by Anesta Corp., where he was responsible for developing corporate strategy and for identifying product licensing partners in the Asia Pacific region. From 1995 to 1998, Mr. Hattersley was employed by Swiss-based JAGO Pharma AG as Director of Program Management, managing its partnerships in North America. He has an experience in product acquisitions, corporate alliances and business and corporate development. Prior to joining Palatin, Mr. Hattersley was Senior Vice President for Mission Pharmacal Company where he was a member of the executive leadership team responsible for reshaping the company. He has also held technical positions at Abbott Laboratories, Syntex Research USA and Alza Corporation between 1986 and 1995. Mr. Hattersley serves as Senior Vice President of Business Development at Palatin Technologies, Inc. since June 2021. Mr. Hattersley received an M.S. degree in Biochemistry in 1986 and an B.A. in Neurobiology in 1985, both from the University of California. He is a member of the Board of Directors for Temple Therapeutics BV.
Positions
- Company NamePalatin Technologies, Inc.Stock CodePTNPositionSenior Vice President of Business DevelopmentColleagues
- CSCarl SpanaCo-Founder, President, CEO & Director
- JKJohn K. A. PrendergastIndependent Non-Executive Chairman
- STStephen T. WillsCFO, COO, Executive VP, Treasurer & Secretary
- BMBurns McClellanVice President of Investor Relations
- SAStephen A. SlusherChief Legal Officer
- AWAlan W. DuntonIndependent Director
- AMArlene M. MorrisIndependent Director
- RCRaymond C. RosenMember of Female Sexual Dysfunction Expert Panel
